loader2
Partner With Us NRI

Company details

10.27
10.59
7.58
26.50
6M Return -49.64%
1Y Return -56.14%
Mkt Cap.(Cr) 85.82
Volume 12,148
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 12,148

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 834.59 Cr FV: 2.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 2,384.58 25,141.00
LAST 3M 44,802.10 -11,969.10
LAST 6M 126,363.03 -152,810.52
LAST 12M 215,488.67 -221,056.82
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
No data found

Information

  • About Company
  • Company Info
  • Listing Info
0
20.96%
39.352
-2.55%
-20.75%
Description
  • Vivimed Labs Ltd is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API`s and Formulations. The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing. The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc. The company operates in two different industry segments, namely Specialty Chemicals and Pharma Manufacturing. The specialty chemicals segment manufactures a range of products active ingredients for home and personal care and personal hygiene products. Pharmaceutical segment is engaged in contract manufacturing and job works. The company`s portfolio has a range of specialty chemicals (active ingredients) supplied to manufacturers of beauty care products like hair care, skin care, sun care and oral care products, industrial care products, such as anti-microbial, anti-fouling agents and biocides and health care products like pharmaceutical finished drug forms for cancer, tuberculosis. The company`s manufacturing capacities are broadly divided into: cGMP manufacturing facility located at Bidar in Karnataka State of India- capacity 250 kl per day. A second cGMP plant, located at Bonthapalli, Hyderabad, India- capacity 400 kl per day. Three Pharmaceutical Finished Dose Plants: at Jeedimetla, Hyderabad, Kashipur, Uttarakhand, Haridwar, Uttarakhand: with complete lines of finished dosage pharmaceutical products. Vivimed Labs Ltd was incorporated on September 22, 1988 as a private limited company with the name Emgi Pharmaceuticals & Chemicals Pvt Ltd. The company was originally promoted by A M Rao. On Rao`s accidental death the company was put for a sale. In the year 1989, Santosh Varalwar and Subhash Varalwar acquired Emgi Pharmaceuticals and Chemicals Ltd. In the year 1990, the company commenced production of Non-Steroidal Anti-Inflammatory Drug (NSAID), `Ibuprofen`. In the year 1994, the company diversified and expanded the product mix by adding other APIs viz. Chlorzoxazone (Skeletal disorders), Nalidixic Acid (Anti-diarrheas) and Flucanazole (Anti-fungal). In April 21, 1994, the company was converted into a public limited company and the name was changed to Emgi Pharmaceuticals & Chemicals Ltd. In the year 1995, the company diversified into specialty chemicals by production of Triclosan. In the year 1996, the company`s R&D was commenced with facilities having an integrated instrumentation for organic synthesis, Microbiology and pre-formulation studies. In April 22, 1997, the company changed their name from Emgi Pharmaceuticals & Chemicals Ltd to Vivimed Labs Ltd. During the year 1998-99, the company expanded the customer base of Triclosan to UK, France, Germany as well as domestic market. In the year 2002, they developed Anti-fungal for usage in High-end cosmetic and pre-formulation blends. In the year 2003, they signed Confidential Sale Agreement with HLL for R&D, scaling up and commercialization of product coded as A123. In the year 2004, the company introduced new products for anti-dandruff and skin care application. They increased the production capacity of Triclosan from 225 MTPA to 480 MTPA. They developed novel synthetic process to manufacture a premium Anti-oxidant and Anti-cancer molecule branded as Vintox. Also, they established manufacturing facilities of Sterile and Small Volume Parentals at Haridwar in Uttarakhand. In the year 2005, the company came out with the public issue and their shares were listed at BSE and NSE. They established a new production facility at Hyderabad for specialty chemicals. They received State Award for Excellence in Exports (SSI GOLD) from Karnataka State Government for excellence in exports. In the year 2006, the company established additional Pharmaceuticals manufacturing facility at Kashipur in Uttarakhand. In May 2008, the company acquired UK-based James Robinson Ltd (now known as Vivimed Labs Europe Ltd) in order to increase their global presence in the specialty chemicals market. During the year 2008-09, the company received new product approvals from several existing clients. They made tie ups with L`oreal and P & G for innovative research on new molecules. The company acquired 80 acres of land at Vishakhapatnam to set up a Greenfield Project to meet growing market demand in Chemical Sector and for Diversification. During the year, the company`s pharma division developed Trimedronate Capsules 250 mg, a cardio- regulator formulation for Russia and CIS Markets and registered the API and formulations in Russia and Ukraine. Also, the company registered two formulations for the Ukranian market, namely Bolarex and Rapidact. During the year 2009-10, the company acquired US-based Harmet International Inc. (now known as Vivimed Labs USA, Inc), as a part of their strategic intent to increase the company`s presence and reach within the NAFTA region. Also, they commissioned their new R&D facility at Mallapur. In June 2010, International Specialty Products (ISP), a New Jersey - based chemical supplier has forged a manufacturing alliance with the company for production of UV absorbers. The manufacturing alliance will allow the two companies to jointly market specific products used in sprays and lotions that include UVA and UVB protective properties. In December 2010, the company commenced commercial production at their new facility for manufacturing of sunscreens set up at Bidar, Karnataka. Also, the company has increased capacities for other ingredients in Oral care/ Hair care segments.

Read More

Registered Address

Plot No 78-A, Kolhar Industrial Area, Bidar, Karnataka, 585403

Tel : 91-8482-232045
Email : yugandhar.kopparthi:vivimeslabs.com
Website : http://www.vivimedlabs.com

Registrar

Aarthi Consultants Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 532660
NSE Code : VIVIMEDLAB
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE526G01021

ICICIdirect Vivimed Labs Ltd FAQ

You can buy Vivimed Labs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Vivimed Labs Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Aug 10, 2022 04:01 PM the closing price of Vivimed Labs Ltd was ₹ 10.35.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Aug 10, 2022 04:01 PM, the market cap of Vivimed Labs Ltd stood at ₹ 85.82.
The latest PE ratio of Vivimed Labs Ltd as of Aug 10, 2022 04:01 PM is 0
The latest PB ratio of Vivimed Labs Ltd as of Aug 10, 2022 04:01 PM is 3.78
The 52-week high of Vivimed Labs Ltd is ₹ 26.50 while the 52-week low is ₹ 7.58 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE